Pfizer discontinues development of filibuvir drug
The drug, which is in mid-stage clinical testing, is facing competition from new hepatitis C treatments developed by Gilead Sciences (GILD) and AbbVie (ABBV). Pfizer spokeswoman Victoria Davis
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
In 2012, the three organizations have partnered to combine Novavax’s vaccine technology, ICGEB’s malaria vaccine research expertise and CPLB manufacturing capability. India’s Department of Biotechnology Vaccine Grand Challenge
Laquinimod, which has crossed the blood brain barrier to potentially have a direct effect on resident CNS inflammation and neurodegeneration in animal models, is a CNS-active immunomodulator exhibiting